Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index.
Massimo
M
Breccia
Giuseppina
G
Loglisci
Adriano
A
Salaroli
Alessandra
A
Serrao
Giuliana
G
Alimena
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001786:Blood Glucose / Q000187:drug effects*; D015992:Body Mass Index; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects*; D055815:Young Adult
D000970:Antineoplastic Agents; D001786:Blood Glucose; D011743:Pyrimidines; C498826:nilotinib